Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
Spinal and bulbar muscular atrophy (SBMA) or Kennedy's disease is a motor neurone disease characterized by muscle atrophy, weakness, contraction fasciculations and bulbar involvement. SBMA mainly affects males, while females are usually asymptomatic. SBMA is caused by expansion of a polyglutamine (polyQ)-encoding CAG trinucleotide repeat in the androgen receptor (AR) gene. AR belongs to the heat shock protein 90 (Hsp90) client protein family. The histopathologic hallmarks of SBMA are diffuse nuclear accumulation and nuclear inclusions of the mutant AR with expanded polyQ in residual motor neurones in the brainstem and spinal cord as well as in some other visceral organs. There is increasing evidence that the ligand of AR and molecular chaperones play a crucial role in the pathogenesis of SBMA. The success of androgen deprivation therapy in SBMA mouse models has been translated into clinical trials. In addition, elucidation of its pathophysiology using animal models has led to the development of disease-modifying drugs, that is, Hsp90 inhibitor and Hsp inducer, which inhibit the pathogenic process of neuronal degeneration. SBMA is a slowly progressive disease by nature. The degree of nuclear accumulation of mutant AR in scrotal skin epithelial cells was correlated with that in spinal motor neurones in autopsy specimens; therefore, the results of scrotal skin biopsy may be used to assess the efficacy of therapeutic trials. Clinical and pathological parameters that reflect the pathogenic process of SBMA should be extensively investigated.
Adachi
H
H
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Waza
M
M
Katsuno
M
M
Tanaka
F
F
Doyu
M
M
Sobue
G
G
D059002:Androgen Receptor Antagonists; D000818:Animals; D016227:Benzoquinones / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D047029:Lactams, Macrocyclic / Q000627:therapeutic use*; D009134:Muscular Atrophy, Spinal / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D011944:Receptors, Androgen / Q000235:genetics
D059002:Androgen Receptor Antagonists; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D011944:Receptors, Androgen; D007987:Gonadotropin-Releasing Hormone; C112765:tanespimycin